Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Iopromide I/mL · 1 trial · 2 indications
A subjective assessment of the 'Quality of Image' (QOI) by 3 blinded readers (BR). QOI-Grades used: Excellent - Good - Poor.
| Arm | Type | Description |
|---|---|---|
| Iopromide 370 mg I/mL | EXPERIMENTAL | Iopromide (Ultravist 370 mg I/mL) administered intravenously |
| Iopromide 300 mg I/mL | EXPERIMENTAL | Iopromide (Ultravist 300 mg I/mL) administered intravenously |
| Name | Type | Description |
|---|---|---|
| Iopromide 370 mg I/mL | DRUG | Iopromide (Ultravist 370 mg I/mL) administered intravenously |
| Iopromide 300 mg I/mL | DRUG | Iopromide (Ultravist 300 mg I/mL) administered intravenously |
Inclusion Criteria: * Is at least 18 years old and clinically indicated for a contrast-enhanced CT of the head or body. Exclusion Criteria: * Patients that are less than 18 years old and do not have a clinical indication for a contrast-enhanced CT of the head or body.
Iopromide I/mL is a small molecule contrast agent used for Computed Tomography (CT), specifically for diagnostic imaging of the head and body. It is being developed by Bayer AG for use in CT procedures to enhance image quality.
Iopromide I/mL is a contrast agent that works by increasing the contrast of blood vessels and tissues during CT imaging. It contains iodine, which absorbs X-rays, allowing better visualization of anatomical structures. It does not target a specific molecular receptor.
Iopromide I/mL is developed by Bayer AG, a multinational pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY on the OTC market.
Iopromide I/mL is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed, and the drug is not currently in active trials.
Iopromide I/mL has one completed Phase 3 clinical trial, NCT00244140, titled 'Ultravist: Safety and Efficacy in Computed Tomography of Head and Body.' The trial enrolled 435 participants across the United States, Colombia, India, and South Korea.
Yes, Iopromide I/mL is the same as Ultravist. The clinical trial NCT00244140, which studied Iopromide I/mL, is titled 'Ultravist: Safety and Efficacy in Computed Tomography of Head and Body,' confirming that Ultravist is the brand name for this drug.